KRON - Kronos Bio announces departure of CFO Head of Corporate Development Al-Wakeel
2023-08-17 08:59:28 ET
More on Kronos Bio
- Kronos Bio gains as CEO buys over $2 million worth of shares
- Kronos Bio to start Phase 3 trial for Entospletinib in AML
- Kronos Bio on go with early-stage cancer study with KB-0742
- Seeking Alpha’s Quant Rating on Kronos Bio
- Earnings data for Kronos Bio
For further details see:
Kronos Bio announces departure of CFO, Head of Corporate Development Al-Wakeel